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SHORT COMMUNICATION
Low prevalence ofhepatitis C infection in hepatocellular carcinoma (HCC)
cases and population controls in Guangxi, a hyperendemic region for HCC
in the People's Republic of China
J-M Yuan', S Govindarajan2, BE Henderson' and MC Yu'
Department of'Preventive Medicine and2Pathology, University ofSouthern California School ofMedicine, Los Angeles, California
90033, USA.
Summary Southern Guangxi, China has one of the highest incidences of hepatocellular carcinoma (HCC) in
the world. Serum samples collected from subjects of an earlier case-control study (39 cases, 41 controls) and
from a random sampling of a residential male cohort (n = 100) were tested for antibodies for the hepatitis C
virus (anti-HCV) using ELISA version 2.0 with confirmation by RIBA version 2.0. Only one of 141 (0.7%,
upper 95% confidence limit, 3.2%) control subjects and none of 39 (upper 95% confidence limit, 6.07%) HCC
cases tested positive for anti-HCV. Our results indicate that hepatitis C infection is not an important
environmental determinant of HCC risk in this hyperendemic region.
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Hepatocellular carcinoma (HCC) varies widely in incidence
worldwide. It is a relatively rare malignancy in the United
States and most of western Europe, but is one of the
commonest cancers in large parts of Asia and sub-Saharan
Africa (Parkin et al., 1992). In the People's Republic of
China, liver cancer represents the third and fourth
commonest causes of cancer death in men and women
respectively (Li et al., 1979). There is considerable
geographical variation in HCC incidence within China, the
high-risk regions are mostly in the southeastern corner of the
country with southern Guangxi exhibiting one of the highest
rates of HCC incidence in the world. In Fusui County in
southern Guangxi, the standardised incidence rate of liver
cancer among men is 120 per 100 000 population per year,
which is 50 times higher than the comparable rate in US
whites (Yeh et al., 1989; Parkin et al., 1992).
Previously, we have shown that chronic infection with the
hepatitis B (HB) virus is a primary risk factor for HCC in
southern Guangxi. In a cohort study of young and middle-
aged men in five rural communities in southern Guangxi, we
demonstrated that approximately one-quarter of the male
population are chronic HB carriers, and that liver cancer is
responsible for half of all deaths in adult men. Over 90% of
subsequent HCC cases were tested positive for hepatitis B
surface antigen (HBsAg) at recruitment, and the incidence of
HCC among HB carriers was close to 1% per year (Yeh et
al., 1989). There was also strong suggestive evidence that
dietary aflatoxin, primarily through ingestion of mouldy
corn, is an important cofactor in liver cancer development in
Guangxi. We observed a 3.5-fold variation in HCC incidence
between the five rural communities which constituted our
cohort, although these subpopulations displayed comparable
prevalence of HBsAg positivity. However, repeated dietary
and food surveys have established that these communities
differed in their mean exposure levels to aflatoxin B1, from a
high of 51.8 mg per person per year to a low of 0.3 mg per
person per year. When HCC rates in these communities were
plotted against their mean load of aflatoxin Bi, an almost
perfectly linear relationship was noted (Yeh et al., 1989).
Relatively little is known about the role of hepatitis C
infection in HCC development in southern Guangxi. Okuno
et al. (1994) tested 186 (168 men, 18 women) patients with
HCC and 48 control subjects (30 men, 18 women) for
antibodies to the hepatitis C virus (anti-HCV) using a
second-generation, Abbott-manufactured enzyme immunoas-
say and noted positivity rates of 5.4% and 0% respectively.
Their findings contrast with those of Zhang et al. (1994)
who used Chinese-manufactured reagents and reported anti-
HCV positivity rates of 33% and 15% in HCC cases and
controls respectively. In this report, we present our findings
on anti-HCV among subjects of an earlier case -control
study (Yeh et al., 1985) and the previously described cohort
(Yeh et al., 1989), both of which were conducted in southern
Guangxi.
Materials and methods
Case-control study
The design of this study has been published (Yeh et al.,
1985). Briefly, cases were HCC patients at the clinic/ward of
the Affiliated Hospital of the Guangxi Medical College in the
city of Nanning. Controls were other clinic/ward patients
whose present illnesses were not hepatitis or other liver
diseases. Controls were individually matched to the cases by
age (within 5 years), sex and clinic vs ward status. All subjects
were recruited during 1982. The mean ages of the cases and
controls were 44.3 and 44.5 years respectively. The original
data set consisted of 50 cases (47 men, 3 women) and 50
controls. Owing to inadequate serum, the present analysis
was restricted to 39 cases and 41 controls.
Blood specimens from all cases and controls were
processed shortly after collection and stored at -20°C until
analysis [for HBsAg, antibodies to the hepatitis B core
antigen (anti-HBc) and antibodies to the hepatitis B surface
antigen (anti-HBs)] in Los Angeles in 1983. Except for that
single thaw, these specimens had been continuously frozen at
-20°C until the present analysis.
Cohort study
The design of this study has been published (Yeh et al.,
1989). Briefly, 7917 male residents of five rural communities
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in southern Guangxi, who were between the ages of 25 and
64 years, were recruited between July 1982 and June 1983. A
25% random sample (n = 1956) of the cohort stratified by age
(10-year groupings) and county of residence (Fusui, Wuming)
was selected for HBsAg testing during May and June 1987.
The present analysis was restricted to a random sample of
100 selected from this subcohort of 1956 men.
Blood specimens from all cohort members were processed
shortly after collection and stored at -20°C. During May
and June 1987, sera from members of the subcohort
(n = 1956) were thawed and tested for HBsAg. Except for
that single thaw, the 100 samples used in the present study
had been continuously frozen at -20°C until testing in our
laboratory (SG).
Laboratory test
All serum samples were tested blindly (i.e. the samples were
identified only by codes, without regard to case or control
status) for anti-HCV using ELISA version 2.0 (Ortho,
Raritan, NJ, USA). Samples which tested positive by ELISA
were confirmed using RIBA version 2.0 (Chiron, Emeryville,
CA, USA).
Results and discussion
Case-control study
One case (out of 39) and one control subject (out of 41)
tested positive by ELISA. Only the positive control was
confirmed by RIBA; the positive HCC case was negative
according to the RIBA test.
Cohort study
Three of the 100 samples from cohort subjects (all of whom
were free of HCC at recruitment) tested positive by ELISA.
However, none ofthese three samples was confirmed by RIBA.
Our results indicate that hepatitis C virus, at best, plays a
relatively minor role in liver carcinogenesis in southern
Guangxi, which has one of the highest recorded incidences
of liver cancer in the world. Among HCC cases, none tested
positive for anti-HCV and the upper 95% confidence limit
for the positivity rate was 6.1%. Among controls, the
observed rate was 0.7% (upper 95% confidence limit,
3.2%). Thus, the present findings are statistically compatible
with those reported by Okuno et al. (1994) who observed
rates of 5.4% and 0% in HCC cases and controls,
respectively, from southern Guangxi. The earlier study used
the second-generation, Abbott-manufactured enzyme immu-
noassay to test all samples but did not employ a confirmatory
assay (such as RIBA) on those samples that tested positive. It
is possible that this lack of confirmation in the study by
Okuno et al. (1994) accounts for their slightly higher rate of
anti-HCV positivity in HCC cases relative to ours.
Recently, we examined anti-HCV serology and HCC in a
cohort study of middle-aged men in Shanghai, another high-
risk Chinese population (incidence of 30.6 per 100 000 men),
and found 1/76 cases and 1/409 controls to be positive for
anti-HCV (Yuan et al., 1995). Our data are similar to those
reported by Ito et al. (1993) and Xu et al. (1990) who studied
anti-HCV prevalence in Nantong and Qidong municipalities,
respectively, which are approximately 60-120 km from
Shanghai. In Nantong, one of 16 (6.3%) cases of HCC and
3/451 (0.7%) control subjects were anti-HCV positive,
whereas the comparable figures in Qidong were 4/50 (8%)
and 0/50 (0%) respectively. We have shown earlier that
hepatitis B infection and dietary aflatoxin are two major risk
factors for HCC in Shanghai (Ross et al., 1992; Qian et al.,
1994). Therefore, current evidence points to hepatitis B
infection and dietary aflatoxin, but not hepatitis C infection,
as the major environmental determinants of liver cancer risk
in the People's Republic of China.
As a measure of quality control, the study samples were
tested concurrently with 58 serum samples collected from
black and white patients with HCC in Los Angeles since
1989. Results of the latter batch were as expected based on
our prior observations on this population at low risk for
HCC. In the current testing, the positivity rates in black and
white males and females were 12/31 and 8/27 respectively.
Our earlier case series assembled during 1984-1989 showed
positivity rates of 12/35 and 3/16 in men and women
respectively (Yu et al., 1990). Thus, there is no evidence
that laboratory irregularities have contributed to an under-
estimation of the frequency of anti-HCV in the current study
population. The fact that the Los Angeles samples have been
in storage for up to 6 years diminishes the likelihood that
degradation of the Chinese samples has contributed to
substantial false-negative results.
Several studies using Chinese-manufactured ELISA kits
have reported higher prevalence of anti-HCV in both HCC
cases and control subjects in southern Guangxi and rural
counties in proximity to Shanghai (Zhang et al., 1994; Chen
et al., 1994; Ye et al., 1994). In Guangxi, Zhang et al. (1994)
noted 33% and 15% positivity in HCC cases and controls
respectively. In Qidong Municipality and Haimen County,
which are adjacent to Nantong Municipality, Chen et al.
(1994) and Ye et al. (1994) reported anti-HCV positivity rates
of 16-17% in HCC cases and 3-4% in control subjects.
None of these studies further examined their ELISA-positive
samples with the RIBA test. The apparent inconsistency
between the studies using US-manufactured kits, i.e. the
present study and those of Xu et al. (1990), Ito et al. (1993),
Okuno et al. (1994) and Yuan et al. (1995), and the three
studies that used Chinese reagents suggests a higher
proportion of false-positives in the latter assays.
In Taiwan, a series of studies based on the patient
population in the Kaohsiung Medical College Hospital
(situated in southern Taiwan) has reported anti-HCV
positivity rates of 20 to 39% in HCC patients, most of
whom were males (Jeng et al., 1991; Chuang et al., 1992; Tsai
et al., 1994a,b,c). All five studies employed either the first-
(Jeng et al., 1991; Chuang et al., 1992) or second-generation
Abbott assay for anti-HCV testing; none used an independent
confirmatory test on positive samples. There was no
appreciable difference in anti-HCV rates between the two
studies using the first-generation kit and the latter three
studies using the second-generation kit. The overall rate of
anti-HCV positivity in HCC cases pooled from the five
studies was 30%. Two other studies conducted in central/
northern Taiwan (also primarily in men) reported lower rates
of anti-HCV among HCC cases (both at around 13%) (Lee
et al., 1992; Chang et al., 1994). The above studies (Jeng et
al., 1991; Chuang et al., 1992; Tsai et al., 1994a,b,c; Chang et
al., 1994) were fairly consistent in their reported rates of anti-
HCV positivity among control subjects; most were in the
range of 2 to 3%. Taken as a whole, the evidence is strong
that Taiwan Chinese patients with HCC and control subjects
have different HCV profiles compared with their counterparts
in the People's Republic of China. It is interesting to note
that one distinguishing feature between Taiwan and mainland
(i.e. People's Republic of China) Chinese is that the former
had had considerably more contact with Japanese who ruled
Taiwan between 1895 and 1945, and whose HCV profile
(both in HCC patients and in the general population) is
dissimilar from the mainland Chinese but quite similar to the
Taiwan Chinese. Studies in Japan have reported anti-HCV
positivity rates of 50-70% among HCC patients and 2-3%
among control subjects (Ito et al., 1991; Tanaka et al., 1991;
Nakashima et al., 1992; Tomimatsu et al., 1993; Hamasaki et
al, 1993; Tanaka et al., 1994; Suga et al., 1994).
There is some evidence that Chinese in Hong Kong, in
terms of HCV profile, are quite similar to their counterparts
in the People's Republic of China. Leung et al. (1992) noted
an anti-HCV positivity rate of 7.3% (31/424) in patients with
HCC (90% were men) and 0.6% (1/175) in control subjects.
The anti-HCV assay used in this study was the first-HCV and liver cancer in China
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generation ELISA manufactured by Ortho Diagnostic
Systems. No independent confirmatory tests were performed
on positive samples.
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